Diabetes news

12/11/18
FacebookTwitter
 

FreeStyle Libre Approved by FDA for Hospitalized Patients During COVID-19 Pandemic


Abbott's FreeStyle Libre 14 day system will allow doctors to remotely monitor their patient's glucose levels. READ MORE

New Program Offers $35 Monthly Copays for Lilly Insulins


Eli Lilly announced a new program that allows people in the US to fill their monthly prescription of Lilly insulin for $35 per month with a copay card.READ MORE

Senseonics Suspends Commercial US Sales of Eversense in Response to COVID-19


On March 26, Senseonics suspended all commercial sales of the Eversense continuous glucose monitor (CGM) in the United States.READ MORE

The Power in Numbers: Change.org’s Affordable Insulin For All Movement


As insulin prices continue to increase in the United States, Change.org is equipping those affected with the tools to speak out.READ MORE

Beyond Type 1 Welcomes New Members to Leadership Council 


The new additions bring a richness of expertise and perspective, representing the Type 1 and Type 2 diabetes communities.READ MORE

The Diabetes Disaster Response Coalition Coronavirus Response


On March 12, the Diabetes Disaster Response Coalition (DDRC) circulated an update to coalition members in response to coronavirus (COVID-19). Here are the steps the organization is taking and other important information to note.READ MORE

New Medicare Plan Will Cap Insulin Copays at $35


Today, the Centers for Medicare & Medicaid Services (CMS) launched a new plan for some Medicare Part D participants to pay a maximum $35 copay for their monthly supply of insulin. READ MORE

Omnipod Closed Loop Technology to be Compatible with Both Abbott and Dexcom CGMs


Abbott and Dexcom announced formal partnerships with Insulet to be compatible as CGMs on the Omnipod Horizon Automated Insulin Delivery System. READ MORE

FDA Approves Triple Combination Pill Trijardy for T2D


On January 27, 2020, the U.S. Food and Drug Administration (FDA) approved Trijardy XR, a triple combination drug of empagliflozin (Jardiance), linagliptin (Tradjenta), and metformin. This is the first triple combination drug available for people with Type 2 diabetes. READ MORE

AADE Rebrands, Changes Name to ADCES


On January 22, 2020, the organization formerly known as the American Association of Diabetes Educators (AADE) announced a change to the organization's name to the Association of Diabetes Care and Education Specialists (ADCES) as part of a large rebrand. The change represents a shift in the organization from the specialty "diabetes educator" to a comprehensive "diabetes care and education specialist" to encompass the range of expertise among specialists who work with people with diabetes. READ MORE

Beyond Type 2 Celebrates One Year Anniversary, Adds New Partner


Today, global diabetes non-profit Beyond Type 1 celebrates the one year anniversary of the launch of Beyond Type 2 - a platform and community serving those impacted by Type 2 diabetes. In 2020, Beyond Type 2 will be supported by many of its original Founding Partners and gains support from new partner Insulet.READ MORE

Researchers See Type 2 Diabetes Develop for the First Time


Researchers have seen Type 2 diabetes (T2D) develop for the first time. A study published this month in Cell Metabolism shows excess fat that spills over from the liver into the pancreas may cause T2D. READ MORE

FDA Investigating Contaminated Metformin, Risk is Low for Type 2 Patients


The FDA, Health Canada, and European Union investigate the presence of cancer-causing NDMA in Type 2 diabetes drug, metformin. The risk to patients is very low.READ MORE

Abbott and Omada Health Partner to Help People With Type 2 Diabetes


On October 14, 2019, Abbott and Omada Health announced a partnership to integrate Abbott's FreeStyle Libre continuous glucose monitoring system (CGM) with Omada Health's digital program for people with Type 2 diabetes. READ MORE

Farxiga Approved in the United States to Treat Heart Failure


On Monday, October 21, 2019, the U.S. Food and Drug Administration (FDA) approved AstraZeneca's diabetes drug, Farxiga, for use in the U.S. to treat and reduce the risks of hospitalization from heart failure in adults with Type 2 diabetes and other cardiovascular risks. READ MORE

Abbott’s FreeStyle Libre Receives Reimbursement in Ontario and Quebec


Abbott FreeStyle Libre announced on Friday, September 13, 2019, it received public reimbursement in Canada's two largest provinces, Ontario and Quebec, for it's FreeStyle Libre System. The news makes FreeStyle Libre the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada. READ MORE

FDA Approves Invokana to Treat Diabetic Kidney Disease


On Monday, September 30, 2019, the U.S. Food and Drug Administration (FDA) approved a new indication for the Janssen Pharmaceutical Companies of Johnson & Johnson's INVOKANA (canagliflozin) to treat diabetic kidney disease and reduce the risk of hospitalization for heart failure in patients with Type 2 diabetes and diabetic nephropathy. READ MORE

FDA Approves First Oral Semaglutide Rybelsus from Novo Nordisk


On September 20, the FDA approved the first oral GLP-1 Rybelsus (semaglutide). Manufactured by Novo Nordisk, the GLP-1 drug showed impressive efficacy in the PIONEER Trial results presented at EASD 2019. READ MORE

Study Shows Combination Therapy Leads to Better Outcomes for Newly Diagnosed T2D Patients


The new study shows combination therapy in patients newly diagnosed with Type 2 diabetes provides better outcomes than metformin alone.READ MORE

FDA Approves First Ready-to-Use Liquid Stable Glucagon Gvoke


On September 10 the FDA approved the Gvoke HypoPen and Gvoke PFS, emergency glucagon rescue devices for the treatment of severe hypoglycemia.READ MORE

Half-Price Generics of NovoLog and NovoLog Mix Announced by Novo Nordisk


Novo Nordisk announced that authorized generic versions of NovoLog and NovoLog Mix will be made available on January 2, 2020.READ MORE

People With Diabetes Forgoing Basic Needs in Order to Survive According to New Studies


According to two studies presented at the American Association of Diabetes Educators 2019 Annual Conference, people with diabetes are forgoing basic needs in the face of rising healthcare costs and taking to underground exchanges of necessary supplies.READ MORE

Nasal Glucagon Baqsimi Approved by the FDA


On Thursday, the Food and Drug Administration approved Eli Lilly and Company's Baqsimi, a non-injectable, nasal glucagon and the first of its kind. READ MORE

Non-Insulin Drug Approved for Kids with T2D by FDA


Victoza, a liraglutide injection, was approved by the U.S. Food and Drug Administration. It's the first non-insulin drug approved for pediatric use in nearly 20 years.READ MORE

Colorado Becomes First State to Pass Bill Capping Insulin Costs


On Wednesday, May 22, Colorado became the first state in the U.S. to put a price cap on insulin.READ MORE

Express Scripts Won’t Cover Lilly’s Generic Insulin


The largest PBM in the U.S. recently released a list of formulary exclusions that included 'Insulin Lispro' as an excluded medication. READ MORE

Previously Healthy from Beyond Type 1 Named Webby People’s Voice Award Winner


Hailed as the “Internet’s highest honor” and “the Oscars of the Internet” The Webby Awards are presented by the International Academy of Digital Arts and Sciences (IADAS) honoring excellence on the Internet.READ MORE

Insulin Manufacturers and PBMs Testify Before Congress


The hearing was contentious throughout, with House members grilling both the manufacturers and the PBM representatives about the reasons for high costs.READ MORE

HALF-PRICE GENERIC OF HUMALOG INSULIN LAUNCHED BY LILLY


On Monday, March 4, Lilly Diabetes announced in a press release that an authorized generic version of Humalog insulin will be available in United States pharmacies for half the list price of Humalog.READ MORE

Research Shows Fridges Might Be Destroying Insulin


A 16-month study has shown that 79% of insulin is kept at temperatures outside of the recommended range. Insulin stored in the fridge is at a much higher risk. READ MORE

How much does it cost to produce insulin?


A recent study sets prices for the future of biosimilars.READ MORE

The Deductible Problem


Over the past two decades, deductibles have been steadily rising and a greater percentage of Americans have been enrolling in high deductible health plans.READ MORE

New Study Reveals the Power of the Diabetes Online Community


You may know the power of the diabetes online community, but does your doctor? Do experts understand what it really means when community members build relationships through social media in the #DOC?READ MORE

Introducing Francine Kaufman: Newest Member of Science Advisory Council


Meet Francine Kaufman M.D., the newest member of the Beyond Type 1 Science Advisory Council! Dr. Kaufman recently spoke with Beyond Type 1 about her history of treating diabetes, her work abroad, the global diabetes landscape, and the future of T1D.READ MORE

FDA Commissioner Makes Statement on Insulin Pricing


In December 2018, the United States FDA Commissioner Scott Gottlieb, M.D., released a statement detailing a handful of new guidances designed to increase competition and bring down prices across the insulin market. The changes are slated to take effect in 2020.READ MORE

All About Danatech – Diabetes Technology on Tap


The Danatech app provides an innovative way for diabetes educators to find information regarding products and other apps that they can readily provide to patients.READ MORE